The University of Southampton
University of Southampton Institutional Repository

The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001)

The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001)
The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001)
Background: 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses (fractions) are at least as safe and effective as the historical standard regimen (50 Gy in 25 fractions) for women after primary surgery for early breast cancer. In this prespecified analysis, we report the 10-year follow-up of the START trials testing 13 fraction and 15 fraction regimens.

Methods: from 1999 to 2002, women with completely excised invasive breast cancer (pT1–3a, pN0–1, M0) were enrolled from 35 UK radiotherapy centres. Patients were randomly assigned to a treatment regimen after primary surgery followed by chemotherapy and endocrine treatment (where prescribed). Randomisation was computer-generated and stratified by centre, type of primary surgery (breast-conservation surgery or mastectomy), and tumour bed boost radiotherapy. In START-A, a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 41·6 Gy or 39 Gy in 13 fractions over 5 weeks. In START-B, a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 40 Gy in 15 fractions over 3 weeks. Eligibility criteria included age older than 18 years and no immediate surgical reconstruction. Primary endpoints were local-regional tumour relapse and late normal tissue effects. Analysis was by intention to treat. Follow-up data are still being collected. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779.

Findings: START-A enrolled 2236 women. Median follow-up was 9·3 years (IQR 8·0–10·0), after which 139 local-regional relapses had occurred. 10-year rates of local-regional relapse did not differ significantly between the 41·6 Gy and 50 Gy regimen groups (6·3%, 95% CI 4·7–8·5 vs 7·4%, 5·5–10·0; hazard ratio [HR] 0·91, 95% CI 0·59–1·38; p=0·65) or the 39 Gy (8·8%, 95% CI 6·7–11·4) and 50 Gy regimen groups (HR 1·18, 95% CI 0·79–1·76; p=0·41). In START-A, moderate or marked breast induration, telangiectasia, and breast oedema were significantly less common normal tissue effects in the 39 Gy group than in the 50 Gy group. Normal tissue effects did not differ significantly between 41·6 Gy and 50 Gy groups. START-B enrolled 2215 women. Median follow-up was 9·9 years (IQR 7·5–10·1), after which 95 local-regional relapses had occurred. The proportion of patients with local-regional relapse at 10 years did not differ significantly between the 40 Gy group (4·3%, 95% CI 3·2–5·9) and the 50 Gy group (5·5%, 95% CI 4·2–7·2; HR 0·77, 95% CI 0·51–1·16; p=0·21). In START-B, breast shrinkage, telangiectasia, and breast oedema were significantly less common normal tissue effects in the 40 Gy group than in the 50 Gy group.

Interpretation: long-term follow-up confirms that appropriately dosed hypofractionated radiotherapy is safe and effective for patients with early breast cancer. The results support the continued use of 40 Gy in 15 fractions, which has already been adopted by most UK centres as the standard of care for women requiring adjuvant radiotherapy for invasive early breast cancer
1086-1094
Haviland, J.S.
569aa43b-15bd-4e9d-b4a5-e68a84334cfe
Owen, J.R.
6ccc7eea-56fc-4aea-b207-d29a2e4b879d
Dewar, J.A.
ccfb195f-253d-4c2d-8eb1-8c6d588a792b
Agrawal, R.K.
3922237b-b4af-40ad-a3c5-f179a8bd5e82
Barrett, J.
057f766e-13b4-4178-8dc5-8755573aa219
Barret-Lee, P.
378e8374-adfa-485a-8511-72208d20b9b1
Dobbs, H.J.
d2f09667-3a91-445b-bd85-4ada278fa3b3
Hopwood, P.
aed6184b-149a-4459-b68e-87a9e22241f0
Lawton, P.A.
ea3a9795-ac11-4b8d-9840-e6a5fbd7d55e
Magee, B.J.
19f89bec-93cb-4efb-9331-2eb1a6e72c8f
Mills, J.
a75c1b76-35a6-4bcb-8492-78b7d4e9f29b
Simmons, S.
9a7930c4-4153-4c7f-963b-65097aaeed08
Sydenham, M.A.
c7b46192-0e56-429f-9e54-37d2fe3b4b0c
Venables, K.
02fd162f-4851-401f-8dc0-a887d6ba6fb9
Bliss, J.M.
84e229a6-c019-47ef-92bb-0875b13f5c18
Yarnold, J.R.
0e51cc2f-3eb1-464f-bf61-d2ac2e86e958
START Trialists Group
Haviland, J.S.
569aa43b-15bd-4e9d-b4a5-e68a84334cfe
Owen, J.R.
6ccc7eea-56fc-4aea-b207-d29a2e4b879d
Dewar, J.A.
ccfb195f-253d-4c2d-8eb1-8c6d588a792b
Agrawal, R.K.
3922237b-b4af-40ad-a3c5-f179a8bd5e82
Barrett, J.
057f766e-13b4-4178-8dc5-8755573aa219
Barret-Lee, P.
378e8374-adfa-485a-8511-72208d20b9b1
Dobbs, H.J.
d2f09667-3a91-445b-bd85-4ada278fa3b3
Hopwood, P.
aed6184b-149a-4459-b68e-87a9e22241f0
Lawton, P.A.
ea3a9795-ac11-4b8d-9840-e6a5fbd7d55e
Magee, B.J.
19f89bec-93cb-4efb-9331-2eb1a6e72c8f
Mills, J.
a75c1b76-35a6-4bcb-8492-78b7d4e9f29b
Simmons, S.
9a7930c4-4153-4c7f-963b-65097aaeed08
Sydenham, M.A.
c7b46192-0e56-429f-9e54-37d2fe3b4b0c
Venables, K.
02fd162f-4851-401f-8dc0-a887d6ba6fb9
Bliss, J.M.
84e229a6-c019-47ef-92bb-0875b13f5c18
Yarnold, J.R.
0e51cc2f-3eb1-464f-bf61-d2ac2e86e958

Haviland, J.S., Owen, J.R., Dewar, J.A., Agrawal, R.K., Barrett, J., Barret-Lee, P., Dobbs, H.J., Hopwood, P., Lawton, P.A., Magee, B.J., Mills, J., Simmons, S., Sydenham, M.A., Venables, K., Bliss, J.M. and Yarnold, J.R. , START Trialists Group (2013) The UK Standardisation of Breast Radiotherapy (START) randomised trials of radiotherapy hypofractionation for treatment of early breast cancer; 10-year follow-up results (CRUK/96/001). Lancet Oncology, 14 (11), 1086-1094. (doi:10.1016/S1470-2045(13)70386-3).

Record type: Article

Abstract

Background: 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses (fractions) are at least as safe and effective as the historical standard regimen (50 Gy in 25 fractions) for women after primary surgery for early breast cancer. In this prespecified analysis, we report the 10-year follow-up of the START trials testing 13 fraction and 15 fraction regimens.

Methods: from 1999 to 2002, women with completely excised invasive breast cancer (pT1–3a, pN0–1, M0) were enrolled from 35 UK radiotherapy centres. Patients were randomly assigned to a treatment regimen after primary surgery followed by chemotherapy and endocrine treatment (where prescribed). Randomisation was computer-generated and stratified by centre, type of primary surgery (breast-conservation surgery or mastectomy), and tumour bed boost radiotherapy. In START-A, a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 41·6 Gy or 39 Gy in 13 fractions over 5 weeks. In START-B, a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 40 Gy in 15 fractions over 3 weeks. Eligibility criteria included age older than 18 years and no immediate surgical reconstruction. Primary endpoints were local-regional tumour relapse and late normal tissue effects. Analysis was by intention to treat. Follow-up data are still being collected. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779.

Findings: START-A enrolled 2236 women. Median follow-up was 9·3 years (IQR 8·0–10·0), after which 139 local-regional relapses had occurred. 10-year rates of local-regional relapse did not differ significantly between the 41·6 Gy and 50 Gy regimen groups (6·3%, 95% CI 4·7–8·5 vs 7·4%, 5·5–10·0; hazard ratio [HR] 0·91, 95% CI 0·59–1·38; p=0·65) or the 39 Gy (8·8%, 95% CI 6·7–11·4) and 50 Gy regimen groups (HR 1·18, 95% CI 0·79–1·76; p=0·41). In START-A, moderate or marked breast induration, telangiectasia, and breast oedema were significantly less common normal tissue effects in the 39 Gy group than in the 50 Gy group. Normal tissue effects did not differ significantly between 41·6 Gy and 50 Gy groups. START-B enrolled 2215 women. Median follow-up was 9·9 years (IQR 7·5–10·1), after which 95 local-regional relapses had occurred. The proportion of patients with local-regional relapse at 10 years did not differ significantly between the 40 Gy group (4·3%, 95% CI 3·2–5·9) and the 50 Gy group (5·5%, 95% CI 4·2–7·2; HR 0·77, 95% CI 0·51–1·16; p=0·21). In START-B, breast shrinkage, telangiectasia, and breast oedema were significantly less common normal tissue effects in the 40 Gy group than in the 50 Gy group.

Interpretation: long-term follow-up confirms that appropriately dosed hypofractionated radiotherapy is safe and effective for patients with early breast cancer. The results support the continued use of 40 Gy in 15 fractions, which has already been adopted by most UK centres as the standard of care for women requiring adjuvant radiotherapy for invasive early breast cancer

Full text not available from this repository.

More information

Published date: 18 September 2013
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 355651
URI: http://eprints.soton.ac.uk/id/eprint/355651
PURE UUID: 9155fe99-23fb-43c8-bd7f-f2dd78557852

Catalogue record

Date deposited: 03 Sep 2013 12:31
Last modified: 22 Jul 2019 16:31

Export record

Altmetrics

Contributors

Author: J.S. Haviland
Author: J.R. Owen
Author: J.A. Dewar
Author: R.K. Agrawal
Author: J. Barrett
Author: P. Barret-Lee
Author: H.J. Dobbs
Author: P. Hopwood
Author: P.A. Lawton
Author: B.J. Magee
Author: J. Mills
Author: S. Simmons
Author: M.A. Sydenham
Author: K. Venables
Author: J.M. Bliss
Author: J.R. Yarnold
Corporate Author: START Trialists Group

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×